Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerome Lewis Avorn, M.D.

Co-Author

This page shows the publications co-authored by Jerome Avorn and Ameet Sarpatwari.
Connection Strength

2.745
  1. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20; 379(12):1097-1099.
    View in: PubMed
    Score: 0.813
  2. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374.
    View in: PubMed
    Score: 0.200
  3. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 11 01; 177(11):1665-1669.
    View in: PubMed
    Score: 0.191
  4. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Aff (Millwood). 2017 02 01; 36(2):362-370.
    View in: PubMed
    Score: 0.181
  5. Factors Influencing Prescription Drug Costs in the United States-Reply. JAMA. 2016 12 13; 316(22):2431-2432.
    View in: PubMed
    Score: 0.180
  6. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30; 316(8):858-71.
    View in: PubMed
    Score: 0.175
  7. State Initiatives to Control Medication Costs--Can Transparency Legislation Help? N Engl J Med. 2016 Jun 16; 374(24):2301-4.
    View in: PubMed
    Score: 0.174
  8. Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med. 2015 Sep 03; 373(10):967-73.
    View in: PubMed
    Score: 0.165
  9. Progress and Hurdles for Follow-on Biologics. N Engl J Med. 2015 Jun 18; 372(25):2380-2.
    View in: PubMed
    Score: 0.161
  10. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802.
    View in: PubMed
    Score: 0.159
  11. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. Clin Pharmacol Ther. 2015 Feb; 97(2):186-93.
    View in: PubMed
    Score: 0.157
  12. Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17; 370(16):1476-8.
    View in: PubMed
    Score: 0.150
  13. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015 Jan 15; 372(3):279-86.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.